Altered Complexin expression in psychiatric and neurological disorders: Cause or consequence?

Molecules and Cells

Volumn 25, Issue 1, 2008, Pages 7-19

  Brose, Nils ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Bipolar disorder; Complexin; Depression; Huntington's disease; Neurodegenerative diseases; Schizophrenia; SNARE complex; Synaptic transmission; Synaptic vesicle fusion

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; CALCIUM; COMPLEXIN; COMPLEXIN 1; COMPLEXIN 2; COMPLEXIN 3; COMPLEXIN 4; GLUTAMIC ACID; MEMBRANE PROTEIN; MESSENGER RNA; PRESENILIN 1; PRESENILIN 2; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CALCIUM TRANSPORT; FETAL ALCOHOL SYNDROME; GABAERGIC TRANSMISSION; GENETIC ASSOCIATION; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL MEMBRANE POTENTIAL; NEUROLOGIC DISEASE; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; SCHIZOPHRENIA; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION; TRAUMATIC BRAIN INJURY; WERNICKE ENCEPHALOPATHY;

ANIMALS; BRAIN; HUMANS; MENTAL DISORDERS; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; SNARE PROTEINS;

MAMMALIA;

EID: 42949109118     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (68)

1. Augustin, I., Rosenmund, C., Sudhof, T.C., and Brose, N. (1999). Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature 400, 457-461.
2. Barr, A.M., Hofmann, C.E., Phillips, A.G., Weinberg, J., and Honer, W.G. (2005). Prenatal ethanol exposure in rats decreases levels of complexin proteins in the frontal cortex. Alcohol Clin. Exp. Res, 29, 1915-1920.
3. Basso, M., Giraudo, S., Corpillo, D., Bergamasco, B., Lopiano, L., and Fasano, M. (2004). Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4, 3943-3952.
4. Beasley, C.L., Pennington, K., Behan, A., Wait, R., Dunn, M.J., and Cotter, D. (2006). Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6, 3414-3425.
5. Butterfield, D.A. and Boyd-Kimball, D. (2004). Proteomics analysis in Alzheimer's disease: new insights into mechanisms of neurodegencration. Int. Rev. Neurobiol. 61, 159-188.
6. Cha, J.H. (2007). Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 83, 228-248.
7. DiProspero, N.A., Chen, E.Y., Charles, V., Plomann, M., Kordower, J.H., and Tagle, D.A. (2004). Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol. 33, 517-533.
8. Drabik, A., Bierczynska-Krzysik, A., Bodzon-Kulakowska, A., Suder, P., Kotlinska, J., and Silberring, J. (2067). Proteomics in neurosciences. Mass Spectrom. Rev. 26, 432-450.
9. Drew, C.J., Kyd, R.J., and Morton, A.J. (2007). Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal. Hum. Mot. Genet. 16, 2288-2305.
10. Dubois, M., Vacher, P., Roger, B., Huyghe, D., Vandewalle, B., Kerr-Conte, J., Patton, F., Moustaid-Moussa, N., and Lang, J. (2007). Glucotoxicity inhibits late steps of insulin exocytosis. Endocrinology 148, 1605-1614.
11. Eastwood, S.L. and Harrison, P.J. (2000). Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. Mol. Psychiatry 5, 425-432.
12. Eastwood, S.L. and Harrison, P.J. (2001). Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP43 and the complexins. Brain Res. Bull. 55, 569-578.
13. Eastwood, S.L. and Harrison, P.J. (2005). Decreased expresssion of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr. Res. 73, 159-172.
14. Eastwood, S.L., Burnet, P.W., and Harrison, P.J. (2000). Expression of complexin I and II mRNAs and their regulation by antipsychotic drugs in the rat forebrain. Synapse 36, 167-117.
15. Eastwood, S.L., Cotter, D., and Harrison, P.J. (2001). Cerebellar synaptic protein expression in schizophrenia. Neuroscience 105, 219-229.
16. Edwardson, J.M., Wang, C.T., Gong, B., Wyttenbach, A., Bai, J., Jackson, M.B., Chapman, E.R., and Morton, A.J. (2003). Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J. Biol. Chem. 278, 30849-30853.
17. Freeman, W. and Morton, A.J. (2004a). Differential messenger RNA expression of complexins in mouse brain. Brain Res. Bull. 63, 33-44.
18. Freeman, W. and Morton, A.J. (2004b). Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res. Bull. 63, 45-55.
19. Giraudo, C.G., Eng, W.S., Melia, T.J., and Rothman, J.E. (2006). A clamping mechanism involved in SNARE-dependent exocytosis. Science 313, 676-690.
20. Glynn, D., Bortnick, R.A., and Morton, A.J. (2003). Complexin II is essential for normal neurological function in mice. Hum. Mol. Genet. 12, 2431-2448.
21. Glynn, D., Drew, C.J., Reim, K., Brose, N., and Morton, A.J. (2005). Profound ataxia in complexin I knockout mice masks a complex phenotype that includes exploratory and habituation deficits. Hum. Mol. Genet. 14, 2369-2385.
22. Glynn, D., Reim, K., Brose, N., and Morton, A.J. (2007a). Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD. Brain Res. Bull. 72, 108-120.
23. Glynn, D., Sizemore, R.J., and Morton, A.J. (2007b). Early motor development is abnormal in complexin 1 knockout mice. Neurobiol. Dis. 25, 483-495.
24. Harrison, P.J. and Eastwood, S.L. (1998). Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia. Lancet 352, 1669-1673.
25. Hazell, A.S. and Wang, C. (2005). Downregulation of complexin I and complexin II in the medial thalamus is blocked by N-acetylcysteine in experimental Wernicke's encephalopathy. J. Neurosci. Res. 79, 200-207.
26. Huntwork, S. and Littleton, J.T. (2007). A complexin fusion clamp regulates spontaneous neurotransmitter release and synaptic growth. Nat. Neurosci. 10, 1235-1231.
27. Ishizuka, T., Saisu, H., Odani, S., Kumanishi, T., and Abe, T. (1999). Distinct regional distribution in the brain of messenger RNAs for the two isoforms of synaphin associated with the docking/fusion complex. Neuroscience 88, 295-306.
28. Jahn, R. and Scheller, R.H. (2006). SNAREs--engines for membrane fusion. Nat. Rev. Mol. Cell. Biol. 7, 631-643.
29. Jockusch, W.J., Speidel, D., Sigler, A., Sorensen, J.B., Varoqueaux, F., Rhee, J.S., and Brose, N. (2007). CAPS-1 and CAPS-2 are essential synaptic vesicle priming proteins. Cell 131, 796-808.
30. Kishi, T. Ikeda, M., Suzuki, T., Kitajima, T., Yamanouchi, Y., Kinoshita, Y., Ozaki, N., and Iwata, N. (2006). No association of complexin1 and complexin2 genes with schizophrenia in a Japanese population. Schizophr. Res. 82, 185-189.
31. Knable, M.B., Barci, B.M., Webster, M.J., Meador-Woodruff, J., and Torrey, E.F. (2004). Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the stanley neuropathology consortium. Mol. Psychiatry 9, 609-620, 544.
32. Lee, H.J., Song, J.Y., Kim, J.W., Jin, S.Y., Hong, M.S., Park, J.K., Chung, J.H., Shibata, H., and Fukumaki, Y. (2005). Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia. Behav. Brain Funct. 1, 15.
33. Lewis, D.A. and Mirnics, K. (2006). Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex. Prog. Brain Res. 158 141-152.
34. McMahon, H.T., Missler, M., Li, C., and Sudhof, T.C. (1995). Complexins: cytosolic proteins that regulate SNAP receptor function. Cell 83, 111-119.
35. Melia, T.J., Jr. (2007). Putting the clamps on membrane fusion: how complexin sets the stage for calcium-mediated exocytosis. FEBS Lett. 581, 2131-2139.
36. Mirnics, K., Middleton, F.A., Marquez, A., Lewis, D.A., and Levitt, P. (2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53-67.
37. Morton, A.J. and Edwardson, J.M. (2001). Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J. Neurochem. 76, 166-172.
38. Morton, A.J., Faull, R.L., and Edwardson, J.M. (2001). Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull. 56, 111-117.
39. Mufson, E.J., Counts, S.E., Che, S., and Ginsberg, S.D. (2006). Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Prog. Brain Res. 158, 197-222.
40. Nakahara, T., Motomura, K., Hashimoto, K., Ueki, H., Gotoh, L., Hondo, H., Tsutsumi, T., Kuroki, T., Hirano, M., and Uchimura, H. (2000). Long-term treatment with haloperidol decreases the mRNA levels of complexin I, but not complexin II, in rat prefrontal cortex, nucleus accumbens and ventral tegmental area. Neurosci. Lett. 290, 29-32.
41. Novikova, S.I., He, F., Cutrufello, N.J., and Lidow, M.S. (2006). Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDITOF-PSD-MS analysis. Neurobiol. Dis. 23, 61-76.
42. Patel, S., Sinha, A., and Singh, M.P. (2007). Identification of differentially dxpressed proteins in striatum of maneb-and paraquat-induced Parkinson's disease phenotype in mouse. Neurotoxicol. Teratol. 29, 578-585.
43. Pennington, K., Beasley, C.L., Dicker, P., Fagan, A., English, J., Pariante, C.M., Wait, R., Dunn, M.J., and Cotter, D.R. (2007). Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol. Psychiatry [Epub ahead of print].
44. Raedler, T.J. and Wiedemann, K. (2006). CSF-studies in neuropsychiatric disorders. Neuro Endocrinol. Lett. 27, 297-305.
45. 2+-dependent neurotransmitter release. Cell 104, 71-81.
46. Reim, K., Wegmeyer, H., Brandstatter, J.H., Xue, M., Rosenmund, C., Dresbach, T., Hofmann, K., and Brose, N. (2005). Structurally and functionally unique complexins at retinal ribbon synapses. J. Cell Biol. 169, 669-680.
47. Rizo, J., Chen, X., and Arac, D. (2006). Unraveling the mechanisms of synaptotagmin and SNARE function in neurotransmitter release. Trends Cell Biol. 16, 339-350.
48. Rosenmund, C., Rettig, J., and Brose, N. (2003). Molecular mechanisms of active zone function. Curr. Op. Neurobiol. 13, 509-519.
49. Salimi, K., Glantz, L.A., Hamer, R.M.; German, T.T., Gilmore, J.H., and Jarskog, L.F. (2008). Regulation of Complexin 1 and Complexin 2 in the developing human prefrontal cortex. Synapse 62, 273-282.
50. Sawada, K., Barr, A.M., Nakamura, M., Arima, K., Young, C.E., Dwork, A.J., Falkai, P., Phillips, A.G., and Honer, W.G. (2005). Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch. Gen. Psychiatry 62, 263-272.
51. Sawada, K., Young, C.E., Barr, A.M., Longworth, K., Takahashi, S., Arango, V., Mann, J.J., Dwork, A.J., Falkai, P., Phillips, A.G., et al. (2002). Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. Mol. Psychiatry 7, 484-492.
52. 2+-synaptotagmin I. Nat. Struct. Mol. Biol. 13, 748-750.
53. Schmidt, O., Schulenborg, T., Meyer, H.E., Marcus, K., and Hamacher, M. (2005). How proteomics reveals potential biomarkers in brain diseases. Exp. Rev. Proteomics 2, 901-913.
54. Sequeira, A. and Turecki, G. (2006). Genome wide gene expression studies in mood disorders. OMICS 10, 444-454.
55. Takahashi, S., Yamamoto, H., Matsuda, Z., Ogawa, M., Yagyu, K., Taniguchi, T., Miyata, T., Kaba, H., Higuchi, T., Okutani F., et al. (1995). Identification of two highly homologous presynaptic proteins distinctly localized at the dendritic and somatic synapses, FEBS Lett. 368, 455-460.
56. Tang, J., Maximov, A., Shin, O.H., Dai, H., Rizo, J., and Sudhof, T.C. (2006). A complexin/synaptotagmin 1 switch controls fast synaptic vesicle exocytosis. Cell 126, 1175-1187.
57. Tannenberg, R.K., Scott, H.L., Tannenberg, A.E., and Dodd, P.R. (2006). Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4. Neurochem. Int. 49, 631-639.
58. Varoqueaux, F., Aramuni, G, Rawson, R.L., Mohrmann, R., Missler, M., Gottmann, K., Zhang, W., Sudhof, T.C., and Brose, N. (2006). Neuroligins determine synapse maturation and function. Neuron 51, 741-754.
59. Witzmann, F.A., Li, J., Strother, W.N., McBride, W.J., Hunter, L., Crabb, D.W., Lumeng, L., and Li, T.K. (2003). Innate differences in protein expression in the nucleus accumbens and hippocampus of inbred alcohol-preferring and nonpreferring rats. Proteomics 3, 1335-1344.
60. Wojcik, S.M. and Brose, N. (2007). Regulation of membrane fusion in synaptic excitation-secretion coupling: speed and accuracy matter. Neuron 55, 11-24.
61. Xue, M., Reim, K., Chen, X., Chao, H.T., Deng, H., Rizo, J., Brose, N., and Rosenmund, C. (2007). Distinct domains of complexin I differentially regulate neurotransmitter release. Nat. Struct. Mol. Biol. 14, 949-958.
62. Yamada, M., Saisu, H., Ishizuka, T., Takahashi, H., and Abe, T. (1999). Immunohistochemical distribution of the two isoforms of synaphin/ complexin involved in neurotransmitter release: localization at the distinct central nervous system regions and synaptic types. Neuroscience 93, 7-18.
63. Yamauchi, Y., Qin, L.H., Nishihara, M., Sawada, K., Kato, K., and Inoue, S. (2005). Vulnerability of synaptic plasticity in the complexin II knockout mouse to maternal deprivation stress. Brain Res. 1056, 59-67.
64. Yi, J.H., Hoover, R., McIntosh, T.K., and Hazell, A.S. (2006). Early, transient increase in complexin I and complexin II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine. J. Neurotrauma 23, 86-96.
65. Zabel, C. and Klose, J. (2004). Influence of Huntington's disease on the human and mouse proteome. Int. Rev. Neurobiol. 61, 241-283.
66. Zabel, C., Sagi, D., Kaindl, AM., Steireif, N., Klare, Y., Mab, L., Peters, H., Wacker, M.A., Kleene, R., and Klose, J. (2006). Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking. J. Proteome Res. 5, 1948-1958.
67. Zink, M., Rapp, S., Gebicke-Haerter, P.J., Henn, F.A., and Thome, J. (2005). Antidepressants differentially affect expression of complexin I and Il RNA in rat hippocampus. Psychopharmacology 181, 560-565.
68. Zink, M., Vollmayr, B., Gebicke-Haerter, P.J., Henn, F.A., and Thome, J. (2007). Reduced expression of complexins I and II in rats bred for learned helplessness. Brain Res. 1144, 202-208.